GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » EPS (Diluted)

Concord Drugs (BOM:538965) EPS (Diluted) : ₹-0.51 (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs EPS (Diluted)?

Concord Drugs's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was ₹0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-0.51.

Concord Drugs's EPS (Basic) for the three months ended in Sep. 2024 was ₹0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-0.51.

Concord Drugs's EPS without NRI for the three months ended in Sep. 2024 was ₹0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-0.51.

During the past 12 months, Concord Drugs's average EPS without NRIGrowth Rate was -128.80% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -2.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Concord Drugs's highest 3-Year average EPS without NRI Growth Rate was 73.00% per year. The lowest was -39.10% per year. And the median was 7.55% per year.


Concord Drugs EPS (Diluted) Historical Data

The historical data trend for Concord Drugs's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs EPS (Diluted) Chart

Concord Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 3.75 1.82 1.06 0.47

Concord Drugs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 -0.24 -0.34 0.03 0.04

Competitive Comparison of Concord Drugs's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's PE Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's PE Ratio falls into.



Concord Drugs EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Concord Drugs's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(4.724-0)/10.000
=0.47

Concord Drugs's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.434-0)/10.850
=0.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Drugs  (BOM:538965) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Concord Drugs EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Concord Drugs's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs Business Description

Traded in Other Exchanges
N/A
Address
Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.

Concord Drugs Headlines

No Headlines